An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors
NCT01262963
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
4
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
GSK2118436
Sponsor
GlaxoSmithKline